Biogen rose the most intraday since June 2021 after a key clinical trial with its partner Eisai showed the therapy lecanemab slowed the progression of Alzheimer’s disease https://t.co/cipzLSx0LX— Bloomberg (@business) September 28, 2022
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)













Quickly


